Scientific Frontline: Extended "At a Glance" Summary: Multiple System Atrophy (MSA)
The Core Concept: Multiple system atrophy (MSA) is a rare, aggressive, and fatal neurological disorder that attacks the autonomic nervous system, severely impacting balance, movement, and critical bodily functions.
Key Distinction/Mechanism: While MSA clinically resembles Parkinson's disease, it typically strikes earlier and progresses much more rapidly; recent research indicates this accelerated decline is linked to microglia (the brain's immune cells) becoming severely exhausted and failing to clear away toxic cellular waste.
Major Frameworks/Components:
- Microglia Dysfunction: The immune cells of the brain lose their ability to act as cellular "garbage collectors," allowing accumulated proteins and dying cells to damage the nervous system.
- Single-Cell RNA Sequencing: An advanced genetic sequencing method utilized to map active genes within individual cell nuclei from the striatum of deceased patients.
- Immune Overactivation Theory: A prevailing hypothesis suggesting the immune system is hyperactive in the disease's early stages, leading to total cellular exhaustion in the later stages.
Future Application: By identifying the exhaustion of microglia as a primary driver of the disease's late-stage progression, researchers can target these specific immune cells for the development of future pharmacological treatments.
Why It Matters: MSA currently has no treatment or cure and is consistently fatal. Uncovering the exact biological mechanisms behind the brain's immune failure provides vital new therapeutic targets for this devastating disease.
A rare and fatal brain disorder with no available treatment or cure, which attacks the nervous system, balance, and the ability to move—this is the reality for patients with multiple system atrophy (MSA). In many ways, MSA resembles Parkinson’s disease, but it strikes earlier and progresses more aggressively.
In a new study, researchers from the University of Copenhagen and Bispebjerg and Frederiksberg Hospital examined brain tissue from patients with MSA to better understand why the disease progresses so rapidly. The brain’s immune cells, known as microglia, appear to play an important role.
Multiple System Atrophy (MSA)
Multiple system atrophy (MSA) is a rare brain disease that in many ways resembles Parkinson’s disease. It attacks the autonomic nervous system and can affect balance and the ability to move, as well as cause problems with urination, sexual function, and blood pressure. The disease is chronic, and there is no treatment or cure. The average age at symptom onset is 55–60 years.
“We expected to see a very active immune system in the brain of patients with MSA because the disease is so aggressive. That is also what we see in patients with Parkinson’s. But we found the opposite. It appears that the brain’s immune cells are sluggish or exhausted, as if they have lost their ability to respond—at least in the later stages of the disease,” says Konstantin Khodosevich, professor at the Biotech Research and Innovation Centre (BRIC) at the University of Copenhagen.
Normally, immune cells function as garbage collectors that clear away waste products in the brain, such as accumulated proteins and dying cells. However, if immune cells fail to perform this function, it can precipitate diseases such as Parkinson’s and MSA.
“We know from other studies that the immune system is very active at the beginning of the disease. Therefore, we have a theory that the immune system may have been overactivated, causing the immune cells to become exhausted. And if the immune cells are not doing their job, the disease can progress more easily,” says Susana Aznar, research leader at Bispebjerg and Frederiksberg Hospital and co-leader of the study.
The researchers emphasize that further studies are needed to clarify whether an overactive immune system can exhaust immune cells.
Analyzing Thousands of Cells
In the study, the researchers analyzed brain tissue donated from three groups: patients with MSA, patients with Parkinson’s disease, and individuals without neurological disease.
The researchers utilized an advanced method established by Konstantin Khodosevich, known as single-cell RNA sequencing, to analyze individual cells. This method makes it possible to map the genes in each cell, even when the samples come from deceased patients.
“We take a very small piece of brain tissue the size of a fingernail and dissolve it into thousands of individual cell nuclei, which we analyze one by one. This allows us to see exactly what is going on in each individual cell type. It gives us a snapshot of what has happened in the brain at the end of the disease process,” explains first author Rasmus Rydbirk, previously a postdoctoral researcher at BRIC and currently a bioinformatician at the University of Southern Denmark (SDU).
In total, the researchers analyzed more than 117,000 cells and several thousand genes per cell. This enabled them to create a detailed map of the brain’s cell types and their conditions across the different patient groups. This process is how the researchers became aware of the immune cells that appeared to behave differently in patients with MSA.
About the Study
In the study, the researchers analyzed tissue samples from seven patients with MSA, twelve with Parkinson’s disease, and ten individuals without neurological disease. MSA is a rare disease, and the number of available brain samples is therefore limited. This limitation reduces statistical power, even though the data resolution is high.
The samples were taken from the striatum, a region of the brain that is crucial for movement and is affected in patients with MSA and Parkinson’s disease.
The researchers analyzed the tissue samples using single-cell RNA sequencing, which makes it possible to determine which genes are active in individual cells—even if they originate from deceased patients.
By comparing the different patient groups, the researchers were able to identify what stood out: immune cells in the brain called microglia appeared to be more inactive in patients with MSA than in those with Parkinson’s disease. However, the study does not establish cause and effect.
Because the brain tissue was donated after death, the analysis does not provide a picture of the entire disease course in patients with MSA, but instead offers a detailed snapshot of what happens in the brain late in the disease.
A Future Treatment?
It is still too early to apply the findings clinically, but the results provide an indication of where to look for potential treatments for MSA.
“MSA is a disease we know very little about, but our study shows that it is worthwhile to further investigate the role of microglia to see whether this could be a potential target for future medical treatment,” says Susana Aznar.
The Danish association for Multiple System Atrophy (Landsforeningen Multipel System Atrofi) welcomes the new research.
“It is devastating to be diagnosed with a fatal disease for which no treatments exist. That is why it is incredibly important that research into MSA is being carried out, so that we can better understand why the disease arises. As research is progressing in many places, it gives hope that in the future it may be possible to find a treatment or a cure,” says Chairperson Inge Vium.
Published in journal: Nature Communications
Title: Single-nucleus brain transcriptomics reveals microglia dysfunction in multiple system atrophy
Authors: Rasmus Rydbirk, Frederik Nørby Friis Sørensen, Jonas Folke, Henriette Haukedal, Andrea Asenjo Martinez, Irene Lisa Vargas, Simone McGarry, Oline Chantell Hollmann, Camila Gherardelli, Sofia Sepulveda, Adam T. Szafran, Michael A. Mancini, Sanne Simone Kaalund, Tomasz Brudek, Lisette Salvesen, Sara Bech, Justyna Okarmus, Peter Kharchenko, Morten Meyer, Claudio Soto, Kristine Freude, Abhisek Mukherjee, Susana Aznar, and Konstantin Khodosevich
Source/Credit: University of Copenhagen
Reference Number: ns051826_01
.jpg)